| Metric | Value | Speaker/Context |
|---|---|---|
| 2026Q2 consolidated net sales | $185.6 million;YoY +50% reported / +49% constant currency | CEO |
| U.S. glaucoma franchise net sales | $118.5 million;YoY +64% | CEO |
| iDose TR sales | 约 $74 million | CEO |
| International glaucoma net sales | $36.6 million;YoY +17% reported / +16% constant currency | CEO |
| Corneal Health net sales | $30.4 million;YoY +48% | CEO |
| Epioxa sales | 约 $11 million | CEO |
| FY2026 net sales guidance | $680 million–$700 million | CEO |
| Prior FY2026 net sales guidance | $620 million–$635 million | CEO |